Galcanezumab
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Galcanezumab: From Migraine Prevention to Heparin Cofactor II Deficiency
One-Sentence Summary
Galcanezumab is a CGRP (calcitonin gene-related peptide)-targeting monoclonal antibody; per the mechanistic notes in this evidence pack, it is used for migraine prevention (this is not confirmed by German/Taiwan regulatory records, as the product is not currently marketed there). TxGNN predicts a possible association with Heparin Cofactor II Deficiency, but the prediction is supported by 0 clinical trials and 0 publications, and the model's own rationale states there is no known biological mechanism connecting the two conditions.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in regulatory data (mechanism notes reference migraine prevention, unconfirmed) |
| Predicted New Indication | Heparin Cofactor II Deficiency |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form. Based on the mechanistic notes accompanying this evidence pack, Galcanezumab is an anti-CGRP monoclonal antibody that blocks pain signaling in the trigeminovascular system, and its established use is migraine prevention.
The three TxGNN-predicted indications in this evidence pack — heparin cofactor II deficiency, antithrombin deficiency type 2, and factor V excess with spontaneous thrombosis — are all rare, genetically-driven coagulation/thrombophilia disorders (SERPIN or coagulation factor gene defects). None of these involve the CGRP signaling pathway, and the evidence pack's own rationale explicitly states there is no known shared molecular pathway, receptor, or downstream signaling overlap between CGRP antibody pharmacology and coagulation cascade regulation.
In other words, this is a case where the TxGNN model assigned high similarity scores (>99%) without an identifiable biological mechanism to support them. This pattern — high score, zero real-world evidence, and an explicit mechanistic disclaimer — should be treated as a candidate requiring further scrutiny rather than a promising repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Galcanezumab is not currently marketed in Germany (0 authorizations on file in this evidence pack).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All three TxGNN-predicted indications (heparin cofactor II deficiency, antithrombin deficiency type 2, factor V excess with spontaneous thrombosis) lack any supporting clinical trials or literature, and the model's own mechanistic rationale states there is no biologically plausible link between CGRP-targeted therapy and these coagulation disorders. Combined with the drug's unconfirmed original indication and lack of market presence in Germany, there is insufficient basis to advance any of these candidates.
To proceed, the following is needed:
- Confirmed original indication and MOA data (from DrugBank API or manufacturer labeling, per DG002)
- Package insert warnings/contraindications (TFDA/BfArM label parsing, per DG001 — currently blocking safety review)
- Any preclinical or mechanistic literature specifically linking CGRP pathway modulation to coagulation factor regulation, before this candidate can move beyond S0
- Reassessment of whether these three predictions represent a systematic TxGNN scoring anomaly (e.g., rare-disease embedding artifact) rather than genuine repurposing signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.